knowledge -WSS

knowledge

author：knowledge 2025-09-07 11:09:30 - browse：13

Why are rich biotechs cutting costs? Has JPM Week already worn off? And what’s going to move markets in 2024?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.

For more on what we cover, here’s the news on Dewpoint Therapeutics; here’s more on biotech in 2024; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： How to save PrEP access — and even expand it
Next article： Videos point to link between seizures and unexplained toddler deaths

WSS

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Feng Zhang CRISPR delivery startup lays off quarter of staff

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Ahead of JPM, here's who's profiting most in health care

3 trends to watch in health tech's hiring outlook for 2024

Doctor of U.S. President Joe Biden says he is fit for duty

leisure time

knowledge

focus

Psychedelics group wrestles with new pharma identity

Change Healthcare cyberattack shows risk of industry consolidation

Moonlake's readout produced a cash windfall. Risks remain

'Vaccine

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Elisabeth Bik tackles the widespread issue of research misconduct

Sports medicine is finally prioritizing gender equality

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

How to save PrEP access — and even expand it

Neuroscience renaissance leads to new crop of psychiatric drugs

leisure time

Neuroscience renaissance leads to new crop of psychiatric drugs

Doctor of U.S. President Joe Biden says he is fit for duty

Elisabeth Bik tackles the widespread issue of research misconduct

How a scoliosis diagnosis changed the life of one young dancer

Feng Zhang CRISPR delivery startup lays off quarter of staff

Chronically ill young patients struggle to find fertility info

leisure time

explore

explore

hotspot